Merck Stock's Surge Was Foreshadowed by Pipeline Promises
From mid-September 2025 to August 2026, Merck (MRK) stock surged nearly 89%, outperforming the S&P 500 and major pharmaceutical peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY). The rise was fueled by positive developments in its drug pipeline. In February 2025, management highlighted over $50 billion of potential revenue from new growth drivers, including enlicitide, an oral cholesterol medication with blockbuster promise. Despite a weak Q2 2025 report showing a 2% revenue drop due to declining GARDASIL sales in China, Merck's CEO emphasized the underappreciated pipeline. The turning point came on September 2, 2025, when enlicitide met all primary goals in its pivotal trial CORALreef Lipids. By August 4, 2026, it had received FDA approval as LIPFENDRA—the first oral PCSK9 inhibitor approved for LDL cholesterol reduction. The stock's rise was not without volatility; shares dipped below the starting point at one stage in mid-2025 before recovering. The key takeaway is that while pipeline promises were public, investors had to wait until late 2025 and early 2026 for tangible proof of success.
Topics: Pharmaceuticals Pipeline Drugs Sales Performance Stock Price Movement